Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children

► Targeted therapy is an useful approach for eliminating MRD to prevent tumor relapse. ► The immunomodulator (MDP-Ab) was constructed by coupling anti-CD10 MAb and MDP. ► On the basis of targeting function of MAb, MDP modulated to kill leukemia cells. ► Anti-CD10 MAb and MDP in the new immunoconjugate kept their own bioactivities. ► MDP-Ab immunomodulator could be a potentially useful drug to eradicate MRD.